



**A Phase 1/2, open-label, dose-escalation, and expansion study to evaluate safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101 as a single agent and in combination with pembrolizumab, lenvatinib or local radiotherapy in patients with advanced or metastatic solid tumors (Keynote B59)**



ONCOLOGY	Phase 1																		
Product Type	Bispecific fusion protein																		
Indication	Advanced or metastatic solid tumors																		
Target	CTLA-4 and IL-2Rβγ																		
MoA(Mechanism of Action)	GI-101 is a bispecific fusion protein containing CD80 and IL-2Rβγ. CD80 of GI-101 targets and blocks CTLA-4, and IL-2 variant selectively binds to IL-2Rβγ to expand and activation of cytotoxic T cell and NK cell.																		
Competitiveness	<div style="display: flex; align-items: flex-start;"> <div style="flex: 1;">  </div> <div style="flex: 2;"> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="text-align: center; background-color: #003366; color: white; border-radius: 50%; width: 40px;">CD80</td> <td style="padding: 5px;"> <ul style="list-style-type: none"> <li>▪ Inhibits CD80/CTLA-4 interaction</li> <li>▪ Inhibits immunosuppressive function of Treg</li> <li>▪ Retains CD80 expression on APCs</li> </ul> </td> </tr> <tr> <td style="text-align: center; background-color: #ccc; border-radius: 50%; width: 40px;">IgG4</td> <td style="padding: 5px;"> <ul style="list-style-type: none"> <li>▪ Low FcγR/C1q affinity</li> <li>▪ No antibody or C-dependent cytotoxicity</li> </ul> </td> </tr> <tr> <td style="text-align: center; background-color: #e67e22; border-radius: 50%; width: 40px;">IL-2v</td> <td style="padding: 5px;"> <ul style="list-style-type: none"> <li>▪ Substituted 2 amino acids to reduce the affinity to IL-2Rα chain</li> <li>▪ Sustained binding to IL-2Rβγ receptors</li> </ul> </td> </tr> </table> </div> <div style="flex: 1; margin-left: 10px;"> <div style="background-color: #003366; color: white; padding: 5px; font-size: 0.8em; margin-bottom: 10px;"> <b>Binding Affinity to CTLA-4 Receptors</b> </div>  <div style="background-color: #003366; color: white; padding: 5px; font-size: 0.8em; margin-bottom: 10px;"> <b>Binding Affinity to IL-2 Receptor (KD, nM)</b> </div> <table border="1" style="width: 100%; border-collapse: collapse; font-size: 0.7em;"> <thead> <tr> <th style="background-color: #eee;">Receptor</th> <th style="background-color: #eee;">Aldesleukin (IL-2 wild type)</th> <th style="background-color: #eee;">NKTR-214 (2-PEG-IL2)</th> <th style="background-color: #eee;">GI-101 (CD80 x IL-2v)</th> </tr> </thead> <tbody> <tr> <td>IL-2Rα</td> <td style="text-align: center;">49.6 (x42)</td> <td style="text-align: center;">486.6 (x8)</td> <td style="text-align: center;">1830 (x1.3)</td> </tr> <tr> <td>IL-2Rβ</td> <td style="text-align: center;">2080</td> <td style="text-align: center;">3951.8</td> <td style="text-align: center;">1360</td> </tr> </tbody> </table> </div> </div> <div style="margin-top: 10px;"> <ol style="list-style-type: none"> <li>1. Tumor/immune cell targeting through CD80</li> <li>2. Inhibition of regulatory T cell through CD80</li> <li>3. Expansion and activation of cytotoxic T cell and NK cell</li> </ol> </div>	CD80	<ul style="list-style-type: none"> <li>▪ Inhibits CD80/CTLA-4 interaction</li> <li>▪ Inhibits immunosuppressive function of Treg</li> <li>▪ Retains CD80 expression on APCs</li> </ul>	IgG4	<ul style="list-style-type: none"> <li>▪ Low FcγR/C1q affinity</li> <li>▪ No antibody or C-dependent cytotoxicity</li> </ul>	IL-2v	<ul style="list-style-type: none"> <li>▪ Substituted 2 amino acids to reduce the affinity to IL-2Rα chain</li> <li>▪ Sustained binding to IL-2Rβγ receptors</li> </ul>	Receptor	Aldesleukin (IL-2 wild type)	NKTR-214 (2-PEG-IL2)	GI-101 (CD80 x IL-2v)	IL-2Rα	49.6 (x42)	486.6 (x8)	1830 (x1.3)	IL-2Rβ	2080	3951.8	1360
CD80	<ul style="list-style-type: none"> <li>▪ Inhibits CD80/CTLA-4 interaction</li> <li>▪ Inhibits immunosuppressive function of Treg</li> <li>▪ Retains CD80 expression on APCs</li> </ul>																		
IgG4	<ul style="list-style-type: none"> <li>▪ Low FcγR/C1q affinity</li> <li>▪ No antibody or C-dependent cytotoxicity</li> </ul>																		
IL-2v	<ul style="list-style-type: none"> <li>▪ Substituted 2 amino acids to reduce the affinity to IL-2Rα chain</li> <li>▪ Sustained binding to IL-2Rβγ receptors</li> </ul>																		
Receptor	Aldesleukin (IL-2 wild type)	NKTR-214 (2-PEG-IL2)	GI-101 (CD80 x IL-2v)																
IL-2Rα	49.6 (x42)	486.6 (x8)	1830 (x1.3)																
IL-2Rβ	2080	3951.8	1360																
Development Stage	Phase 1																		
Route of Administration	Intravenous, Q3W																		